Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENC-X02
- Development stage
- Preclinical
- Lead developer
- Encellin
- Modality
- Cell Therapies
- Administration
- Implant
01
Overview
ENC-X02 is an encapsulated cell therapy being developed by Encellin for the treatment of Type 1 Diabetes. The therapy utilizes Encellin's proprietary Encapsulated Cell Replacement Therapy (ENCRT) platform, which consists of a soft, nanoporous, biocompatible pouch designed to house and protect therapeutic cells from the host's immune system while allowing the exchange of nutrients, oxygen, and therapeutic biomolecules. ENC-X02 encapsulates an undisclosed renewable cell payload intended to provide endocrine cell replacement, offering a potential long-term treatment that avoids the need for chronic systemic immunosuppression. The program is currently in preclinical development.
Beyond the preview
Go deeper on ENC-X02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ENC-X02.